Corporate venture funds fill drop off in biotech investment

11/15/2011 | Bloomberg Businessweek

Corporate venture funds are increasingly filling biotech firms' funding needs, according to analysts. Corporate venture funds were tied to 25% of early-stage U.S. biotech financing deals during the first half of 2011, compared with 15% in all of 2010, according to PricewaterhouseCoopers and the National Venture Capital Association. Amgen Ventures said it has funded 26 companies since it started in 2004.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA